Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: June 25, 2025

Renata Block, DMSc, MMS, PA-C, is a board-certified physician assistant and instructor at Rush University in Chicago, Illinois, a 

 editorial advisory board member, and the past president of the Society of Dermatology Physician Associates (SDPA) and the Illinois SDPA.

Explore insights on benzoyl peroxide and benzene risks in acne treatment from experts Renata Block, PA-C, and John Barbieri, MD, MBA.

Derm Dispatch: Navigating Benzoyl Peroxide Safety and Acne Treatment Advancements

Discover the latest advancements in vitiligo treatment and awareness as Dermatology Times highlights this year's progress during Vitiligo Awareness Month.

Celebrating World Vitiligo Day 2025 with Dermatology Times

Sonia Batra, MD, dispels common myths and shares expert tips on summer skin care for acne, emphasizing sun protection and tailored regimens.

Summer Skin Care and Sunscreen Guidance for Patients with Acne

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Sonia Batra, MD, is a dual board-certified dermatologist, micrographic dermatologic surgeon, and clinical assistant professor at USC Keck School of Medicine. She also founded her own practice, Batra Dermatology, in Santa Monica, California

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

 its approval of dupilumab (Dupixent; Regeneron Pharmaceuticals, Inc. and Sanofi) for adults with bullous pemphigoid (BP), marking the first and only targeted therapy for this patient population.

"Dupilumab's approval for the bullous pemphigoid indication is a huge step forward for the immunobullous field,"said Christopher Bunick, MD, PhD, associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, and editor in chief of 

, in a statement. "BP patients have long had to utilize systemic and topical steroids, long-term antibiotics, and other traditional immunosuppressants, with moderate degrees of efficacy and questionable safety risks. Dupilumab represents a major advance in the care of the BP patient, especially elderly patients whose long-term use of the previous therapies carries potential health risks. Dupilumab will change the lives of many BP patients, and I share the excitement with my dermatology colleagues that we now have an effective, safe, on-label immunotherapy for BP."

The approval is supported by positive data from the pivotal phase 2/3 LIBERTY-BP ADEPT study.

 The randomized, double-blind, placebo-controlled study assessed dupilumab in a cohort of 106 adults with moderate to severe BP over the course of 52 weeks. Patients received dupilumab or placebo plus oral corticosteroids (OCS), which were tapered starting as early as week 4 if disease control was maintained, with a goal of stopping OCS by week 16. 

At 36 weeks, 18.3% of dupilumab-treated patients achieved sustained disease remission vs 6.1% with placebo. Clinically meaningful itch reduction was seen in 38.3% vs 10.5%, and median cumulative OCS use was lower (2.8g vs 4.1g).

Common adverse events included arthralgia, conjunctivitis, blurred vision, herpes infections, and keratitis. One dupilumab-treated patient was reported to develop acute generalized exanthematous pustulosis.

Dupilumab also met all secondary endpoints in the ADEPT study with statistically significant results.

Notably, 41% of patients achieved a ≥90% reduction in disease severity vs 10% on placebo, and 40% reported meaningful itch relief vs 11% on placebo. A greater reduction with dupilumab was observed saw improvements in both disease severity (77% vs 50%) and itch (52% vs 27%), and dupilumab treatment resulted in longer periods of corticosteroid-free remission (40 days vs 13 days).

Additional studies of dupilumab in BP have further demonstrated its efficacy in this indication.

A 2025 comparative study of biologics for BP published in the 

 reported that dupilumab demonstrated superior outcomes to omalizumab (Xolair; Genentech and Novartis Pharmaceuticals Corporation), achieving disease control in 90.6% of patients and complete remission in 87.1%, with lower relapse (10.3%) and discontinuation rates (15.6%).

Dupilumab also led to faster responses, though differences were not statistically significant. Both drugs were well-tolerated, but dupilumab was especially effective in patients with immunotherapy- or gliptin-associated BP, where all treated individuals achieved disease control without relapse.

In the press release, Patrick Dunn, Executive Director of the International Pemphigus and Pemphigoid Foundation, said, “People affected by bullous pemphigoid endure unrelenting itch and painful blisters that can damage the skin. Until now, these primarily elderly patients have had limited therapeutic options available, with potential side effects that have often added to their burden. The approval of Dupixent for bullous pemphigoid brings a novel treatment approach to patients and their caregivers, and we are grateful for the tireless efforts of the scientific community who helped us reach this critical milestone." Representatives from Sanofi and Regeneron also shared their thoughts.

“This approval extends the remarkable ability of Dupixent to transform treatment paradigms for people living with a variety of diseases with underlying type 2 inflammation, from common conditions like asthma and atopic dermatitis, to rarer ones such as eosinophilic esophagitis and prurigo nodularis, and now including bullous pemphigoid," George D. Yancopoulos, MD, PhD, Board co-Chair, President, and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent, said. "Dupixent has shown the potential to improve the most challenging effects of bullous pemphigoid, while helping some patients achieve sustained disease remission and decreased oral corticosteroid use. Additionally, this approval further reinforces the demonstrated safety profile of Dupixent in a broad age range of patients, from infants to elderly people, and across dermatological, respiratory, and gastrointestinal diseases.”

"Until now, treating bullous pemphigoid was very challenging for elderly patients struggling with the debilitating impact of blisters and lesions, and potentially co-morbid conditions. By addressing two central drivers of the underlying type 2 inflammation that contributes to bullous pemphigoid, Dupixent is the first targeted medicine to allow patients the potential to achieve sustained remission and reduce itch.

 This approval in the US is important for the thousands of patients living with bullous pemphigoid, and we look forward to working with regulators around the world to bring this innovative medicine to more patients in need," said Alyssa Johnsen, MD, PhD, Global Therapeutic Area Head of the Immunology and Oncology Development at Sanofi.

In reflecting on the real-world impact of dupilumab for bullous pemphigoid, 

 Editorial Advisory Board member Matthew Zirwas, MD, offered a summary that highlights his optimism:

"Way better than the data. If I had to summarize my thoughts on dupilumab in bullous pemphigoid in 5 words or less, I'd use those 5. When we have the first drug for a disease, the patients who get enrolled in the trials are generally 'the worst of the worst.' This was true for dupilumab in atopic dermatitis, and it is true for dupilumab in bullous pemphigoid," Zirwas, a board-certified dermatologist at Bexley Dermatology in Columbus, Ohio, said. "For context, in atopic dermatitis, less than 40% of patients reached the primary endpoint in the dupilumab trials (doesn't sound very impressive), but in real life, only 10% of patients stop dupilumab because of inadequate efficacy. In bullous pemphigoid, I think it will be even more pronounced (for a number of good reasons); while less than 20% of patients hit the primary endpoint in the trials, based on the overall picture, I am betting that dupilumab will be very effective in 90% of patients in our offices."

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid. News release. Sanofi. June 20, 2025. Accessed June 20, 2025. 

https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-20-05-00-00-3102518

Murrell DF, Joly P, Werth VP, et al. Study design of a phase 2/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT [published correction appears in Adv Ther. 2024 Jul;41(7):3014-3015. doi: 10.1007/s12325-024-02886-x.]. 

Efficacy and safety of dupilumab in patients with bullous pemphigoid: results From LIBERTY-BP ADEPT Phase 2/3 Study. Late Breaking Research Session 2. Presented at 2025 American Academy of Dermatology Annual Meeting; March 8, 2025; Orlando, Florida.

Avallone G, Maronese CA, Zussino M, et al. Effectiveness of dupilumab and omalizumab in bullous pemphigoid: A nationwide retrospective cohort study. 

 Published online April 16, 2025. doi:10.1111/1346-8138.17742


The US FDA has approved dupilumab (Dupixent) for adults with bullous pemphigoid, marking it as the first targeted therapy for this condition. The approval is based on the LIBERTY-BP ADEPT study, which demonstrated significant improvements in disease remission, itch reduction, and reduced corticosteroid use. Dupilumab outperformed omalizumab in a comparative study, showing superior disease control and remission rates. Experts highlight the drug's potential to transform treatment paradigms for type 2 inflammation-related diseases, offering a novel approach for patients with limited therapeutic options.

Dupilumab gains FDA approval as the first targeted therapy for bullous pemphigoid, offering hope for effective treatment and improved patient outcomes.

FDA Approves Dupilumab, First and Only Targeted Medicine for Bullous Pemphigoid

I'm sorry, but it seems there is no article text provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

Polls 

POLL: What is the Most Common Type of Mole Found on Adults? 

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

 conference in Nashville, Tennessee, Eli Lilly and Company shared final results from the phase 3b ADmirable trial of lebrikizumab (Ebglyss).

This is the first study to evaluate lebrikizumab’s effectiveness and safety in adult and adolescent patients with pigmented skin and atopic dermatitis (AD), as this population is typically underrepresented in clinical trials.

) included 90 patients 12 years and older (weight: ≥ 40 kg) with moderate to severe AD and pigmented skin, according to the Fitzpatrick skin type scale (IV, V, or VI). Participants self-identified as Black or African American, Asian, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander. The mean age of patients was 40.7 years. Approximately 43.3% of participants had a Fitzpatrick skin phototype of IV.

"Skin pigmentation matters in evaluating patients with atopic dermatitis, because from a medical perspective, the disease presents differently in darker skin tones vs lighter (eg, redness can be more subtle, pigmentation more prominent, and diagnosis and evaluation more challenging). Additionally, in the next 20 years, people who identify as American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian, or other Pacific Islander are projected to represent more than half of all Americans, which drives our urgency to invest in clinical research that helps address longstanding medical gaps in these populations. ADmirable is the first dedicated study to evaluate the efficacy and safety of Ebglyss in adult and adolescent patients with AD in these patients frequently underrepresented in clinical trials," said Anabela Cardoso, MD, senior vice president of immunology medical affairs at Eli Lilly and Company, in an interview with 

The patients received lebrikizumab 250 mg (500-mg loading dose at baseline and week 2) subcutaneously every 2 weeks for 16 weeks. Then, from weeks 16 to 24, those who responded to treatment received lebrikizumab 250 mg once every 4 weeks; those with inadequate response continued with the dosage every 2 weeks.

Respondents were defined as having an Investigator’s Global Assessment score of 0 or 1 with a 2-point or greater improvement (IGA 0/1) or 75% or greater improvement in Eczema Area and Severity Index (EASI 75). The primary end point of the study was achieving an EASI score of 75 at week 16. Secondary end points revolved around safety and efficacy using PDCA Derm, assessing cutaneous postinflammatory hyperpigmentation and hypopigmentation.

Approximately 68.9% of patients began the trial with moderate disease (IGA = 3) with a mean EASI of 26.4 and an average Pruritus Numeric Rating Scale (NRS) score of 7. At week 16, EASI 75, EASI 90, and IGA 0/1 were achieved by 69.2%, 44.9%, and 44.9% of patients, respectively. This includes more than 88% of patients with the darkest skin tones (Fitzpatrick V and VI). Approximately 73% of respondents were able to switch to a once-monthly maintenance dose after 16 weeks.

Nearly 60% of patients observed a 4-point or greater improvement in Pruritus NRS. These numbers increased at week 24 with EASI 75, EASI 90, and IGA 0/1 achieved by 78.4%, 47.3%, and 54.1% of patients, respectively. Moreover, 61.5% of participants had a 4-point or greater Pruritus NRS improvement.

"This new data demonstrating improvement in signs and symptoms (including itch) through 24 weeks of treatment helps confirm the efficacy of lebrikizumab in patients with skin of color – a population for which data is often lacking. Being able to communicate to my patients that the treatment I am recommending has established efficacy and safety in populations that reflect their background goes a long way in establishing trust and encouraging adherence to therapy," said Andrew Alexis, MD, professor of clinical dermatology and vice-chair for diversity and inclusion at Weill Cornell Medicine, in a statement to 

Additionally, 4-point or greater improvements in the Dermatology Life Quality Index were reached by 71.7% and 72.9% of patients at weeks 16 and 24, respectively. More than 64% of patients with hyperpigmented lesions and 25% with hypopigmented lesions showed improvement after 24 weeks. Most treatment-emergent adverse effects were mild or moderate, with only 1 reported case of conjunctivitis and injection site reaction. None of the adverse events were serious, and the drug did not need to be discontinued. This safety profile is consistent with previous long-term trials of lebrikizumab, regardless of dosage and frequency.

"Being able to communicate to my AD patients with skin of color that treatment with lebrikizumab has a high success rate in improving not only the signs and symptoms of AD, but also the sequela of postinflammatory hyperpigmentation, is extremely impactful and aligns with their treatment goals," said Alexis.

Overall, patients with skin of color and moderate to severe AD severity responded well to lebrikizumab after 24 weeks, with improvements in symptoms such as itch and hyperpigmentation. Response was noted as early as week 16 and continued to improve throughout the trial with a favorable safety profile.

"These new, 24-week data from ADmirable—the first dedicated study for evaluating the efficacy and safety of Ebglyss in adult and adolescent patients with pigmented skin and moderate-to-severe atopic dermatitis—reinforce the efficacy and safety of Ebglyss as a first-line biologic, following prescription topicals, with once-monthly maintenance dosing after the 4-month initial dosing for adults and adolescents, regardless of skin tone. These add to the robust and extensive data supporting Ebglyss's value for a broad range of patients with moderate to severe atopic dermatitis," Cardoso concluded.

1. Alexis A, Moiin A, Waibel J, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: final 24-week results from the phase 3b, open-label ADmirable study. Presented at: 2025 Revolutionizing Atopic Dermatitis (RAD) Conference; June 6-7, 2025; Nashville, TN.

2. Lilly's Ebglyss (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at 3 years in half of patients with moderate-to-severe atopic dermatitis. News release. Eli Lilly. March 7, 2025. Accessed June 7, 2025. 

https://investor.lilly.com/news-releases/news-release-details/lillys-ebglyssr-lebrikizumab-lbkz-single-monthly-maintenance

Lebrikizumab demonstrated efficacy and safety in treating moderate-to-severe atopic dermatitis (AD) in patients with pigmented skin, a group often underrepresented in clinical trials. The phase 3b ADmirable trial included 90 participants aged 12 and older, with significant improvements observed in Eczema Area and Severity Index (EASI) and Pruritus Numeric Rating Scale (NRS) scores by week 16, which further improved by week 24. The study reported a favorable safety profile, with most adverse effects being mild or moderate, and no serious events necessitating discontinuation of the drug.

At RAD 2025, Eli Lilly revealed promising results for lebrikizumab in treating atopic dermatitis in patients with skin of color.

Late-Breaking Data: Lebrikizumab Demonstrates Efficacy in Patients With Skin of Color With AD

As we begin 2025 with a new president and a Republican majority in both houses of Congress, it is a good time to consider aspects of the current tax law that are set to expire at the end of 2025, as well as various tax proposals President Donald Trump made throughout his campaign. Understanding these potential changes will help you implement tax planning for 2025 and beyond.

The Tax Cuts and Jobs Act (TCJA), enacted in December 2017, introduced substantial amendments to the US tax code, aiming to streamline tax processes, provide economic stimulation, and foster investment. These changes affected various aspects of individual and corporate taxation. While some provisions are temporary, others offer long-term shifts in taxation policy. Here, we will examine some of the temporary provisions set to expire December 31, 2025, along with proposals President Trump has made regarding those provisions.

The TCJA reduced tax rates for most individual taxpayers, with the top rate falling to 37% from the previous 39.6%. This reduction benefited high-income earners but was designed to cover a broad swath of income brackets, providing financial relief across socioeconomic groups.

A significant change under the TCJA was the doubling of the standard deduction to what is for 2025 $15,000 for individuals and $30,000 for married couples. These adjustments reduced the number of taxpayers itemizing deductions, simplifying the tax filing process for many.

The TCJA doubled the child tax credit to $2000 per child and expanded its eligibility criteria, allowing more families to qualify. Up to $1400 of the credit became refundable, enabling low-income families with little tax liability to benefit.

The TCJA capped the state and local tax (SALT) deduction at $10,000, significantly impacting taxpayers in high-tax states. Critics argued that this disproportionately affected those in states with substantial state and local taxes.

The TCJA essentially doubled the estate tax exemption, which has since been indexed for inflation to its current 2025 level of $13.99 million per individual. Estates with taxable assets above this amount will be taxed at 40%.

Barring passage of any new federal tax law, as of January 1, 2026:

Individual tax brackets will revert to previous levels, with the top tax bracket at 39.6%.

The standard deduction will be halved, making it more beneficial for many taxpayers to itemize deductions again.

The cap for mortgage acquisition debt on which interest is deductible will go back to $1 million from the current $750,000.

State and local income taxes and real estate and property taxes will again be fully deductible.

The federal estate tax exemption will be cut in half.

During his campaign, however, President Trump presented proposals that could modify these provisions or eliminate the year-end expiration date. These include making permanent the lower tax brackets and increased standard deduction, as well as increasing the child tax credit to $5000 per child without income limits, an adjustment intended to provide more support for families, particularly in light of rising childcare costs. He also mentioned allowing the cap on state and local income tax (SALT) deductions to lapse, restoring higher deduction possibilities, and proposed additional deductions for interest on loans for US-built cars and for home generators in natural disaster-prone areas. He has also suggested making the higher estate tax exemption permanent or repealing the estate tax altogether.

The TCJA introduced a 20% deduction for qualified business income from pass-through entities (eg, LLCs, partnerships, and S corporations). This provision is also temporary, expiring in 2025. President Trump proposed making this deduction permanent, citing its importance for small businesses. However, medical practices are considered a specified service trade or business (SSTB) and are not eligible for this deduction unless an individual taxpayer’s income is below certain threshold amounts ($494,600 for married taxpayers filing jointly in 2025).

Tax rates for C corporations were permanently reduced to 21% under the TCJA. President Trump, however, has proposed a further rate cut for corporations to 20% or even 15%.

The general expectation is that President Trump will try to pass a new tax law early in his term since Republicans have a majority in both houses. If individual tax rates continue at a top rate of 37%, with expanded brackets of lower tax rates, continuing to fund Roth IRA accounts will make sense for many taxpayers. Recent gains in the stock market have increased the balances in qualified retirement plans. Traditional plans such as 401(k)s, 403(b)s, and IRAs will have required minimum distributions (RMDs) when taxpayers reach age 73 or 75, depending on their year of birth. Roth accounts do not have such requirements. For those who have more savings in retirement plans than they will need, converting some of the funds to a Roth, or adding current funding to Roth accounts, could make sense.

If the SALT cap is allowed to expire while standard deduction increases are extended, many taxpayers will again find it more beneficial to itemize deductions rather than take the increased standard deduction. Allowing the mortgage interest deduction on up to $1 million of debt would further enhance itemized deductions for many taxpayers. Itemizing deductions will also make charitable contributions more beneficial; thus, donating appreciated assets to charity can be a key component of efficient giving.

For taxpayers who are owners of pass-through entities, an extension of the Section 199A qualified business income (QBI) deduction will extend the tax cuts on business income. If that business is an SSTB such as a medical practice, utilizing tools such as a cash balance plan to increase deductions may help bring taxable income below the threshold amounts, thereby making the QBI deduction allowable.

Efficient tax planning in 2025 will require paying attention to proposed tax law changes and working with your advisers when any new legislation is passed to make sure you fully understand how to create a tax-efficient wealth plan.

 is a certified public accountant and author of more than a dozen books for physicians. She is a partner in the wealth management firm OJM Group (

) and can be reached at 877-656-4362 or 

OJM Group, LLC (“OJM”) is an SEC-registered investment adviser with its principal place of business in the State of Ohio. SEC registration does not constitute an endorsement of OJM by the SEC nor does it indicate that OJM has attained a particular level of skill or ability. OJM and its representatives are in compliance with the current notice filing and registration requirements imposed upon registered investment advisers by those states in which OJM maintains clients. OJM may only transact business in those states in which it is registered or qualifies for an exemption or exclusion from registration requirements. For information pertaining to the registration status of OJM, please contact OJM or refer to the Investment Adviser Public Disclosure web site 

For additional information about OJM, including fees and services, send for our disclosure brochure as set forth on Form ADV using the contact information herein. Please read the disclosure statement carefully before you invest or send money.

This article contains general information that is not suitable for everyone. The information contained herein should not be construed as personalized legal or tax advice, or as a recommendation of any particular security or strategy.

There is no guarantee that the views and opinions expressed in this article will be appropriate for your particular circumstances. Tax law changes frequently; accordingly, information presented herein is subject to change without notice. You should seek professional tax and legal advice before implementing any strategy discussed herein.

As 2025 begins with a new administration and Republican congressional majority, attention turns to the expiring provisions of the Tax Cuts and Jobs Act (TCJA) and President Trump's tax proposals. Key TCJA provisions set to expire include lowered tax brackets, increased standard deductions, and enhanced child tax credits. Trump's proposals aim to make these changes permanent, increase the child tax credit, and adjust SALT deductions. Tax planning strategies should consider potential legislative changes, focusing on Roth IRA conversions, itemized deductions, and qualified business income deductions for pass-through entities.

Key 2025 tax law changes for dermatologists include expiring TCJA provisions, potential rate adjustments, and new deduction policies under Trump.

Sonia Batra, MD

Articles

Latest Updated Articles